4.3(top 3%)
Impact Factor
4.5(top 3%)
extended IF
91(top 4%)
H-Index
2.1K
authors
3.4K
papers
69.5K
citations
4.2K
citing journals
40.3K
citing authors

Most Cited Articles of Investigational New Drugs

TitleYearCitations
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria1992517
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors2017498
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic1999421
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas1994373
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme2005346
Matrix metalloproteinase inhibitors1997327
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine2014323
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development2000265
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy2015260
Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity1999245
Role of formulation vehicles in taxane pharmacology2001240
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma2011230
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction2011229
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma2014226
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer2013220
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients2007215
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials1999206
Proteasome inhibition: a new strategy in cancer treatment2000197
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer2012193
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor2008192
Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results1999178
Aurora kinase inhibitors: progress towards the clinic2012176
Ipilimumab associated hepatitis: imaging and clinicopathologic findings2013172
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy2012164
Development of artemisinin compounds for cancer treatment2013157